Compare VanEck Rare Earth/Strategic Metals (REMX) vs TG Therapeutics Inc (TGTX) Price & Performance

REMX (VanEck Rare Earth and Strategic Metals ETF) trades at $60.97, down 1.47% with a bearish technical outlook. The ETF faces selling pressure across moving averages and oscillators, though RSI readings below 14 suggest potential oversold conditions. Recent news highlights strategic importance of rare earth metals amid U.S. efforts to reduce dependence on China, with Bank of America increasing its stake by 72.1% in the latest quarter.

The ETF offers exposure to 38 global rare earth companies but carries high volatility (~50% annualized) and significant China exposure. While geopolitical trends support long-term demand, current technical weakness and sector-specific risks warrant caution. The reshoring trade provides structural tailwinds, but investors should be prepared for elevated price swings.

TG Therapeutics (TGTX) trades at $55.37, up 4.57% today, but faces a bearish technical signal with recent earnings misses. Strong revenue growth is driven by BRIUMVI, with 2026 guidance raised to $950 million, though profitability is pressured by investments. A shareholder investigation and volatile cash flows add uncertainty, while analyst consensus remains bullish with an $80.50 price target.

The outlook hinges on BRIUMVI's market share gains and subcutaneous formulation progress, offering upside if execution succeeds. Risks include the fiduciary investigation, competitive pressures, and reliance on a single product. The stock presents a high-risk, high-reward opportunity, with current valuation reflecting growth expectations but vulnerable to setbacks.